Immunoregulatory effects of mesenchymal stem cell-derived extracellular vesicles on T lymphocytes

Cell Transplantation

Volumn 24, Issue 12, 2015, Pages 2615-2627

  Fattore, Andrea Del ^a   Luciano, Rosa ^a   Pascucci, Luisa ^b   Goffredo, Bianca Maria ^a   Giorda, Ezio ^a   Scapaticci, Margherita ^c   Fierabracci, Alessandra ^a   Muraca, Maurizio ^d  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c SAN CAMILLO HOSPITAL   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

Extracellular vesicles(EVs); Immunomodulation; Mesenchymal stem stromal cells(MSCs); Regulatory T cells

Indexed keywords

CD28 ANTIBODY; CD3 ANTIBODY; CELL ANTIBODY; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; KYNURENINE; TRYPTOPHAN; UNCLASSIFIED DRUG; CARRIER PROTEIN; CD28-BINDING PROTEIN, HUMAN; CD3 ANTIGEN; IL10 PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ADULT; ANALYTIC METHOD; APOPTOSIS; ARTICLE; CELL PROLIFERATION; ENZYME ACTIVITY; EXOSOME; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOREGULATION; IN VITRO STUDY; LEUKOCYTE CULTURE; LIMIT OF DETECTION; MALE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL DERIVED EXTRACELLULAR VESICLE; NORMAL HUMAN; PARTICLE SIZE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SCANNING ELECTRON MICROSCOPY; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TRANSMISSION ELECTRON MICROSCOPY; TUNABLE RESISTIVE PULSE SENSING; B LYMPHOCYTE; BONE MARROW CELL; CELL CULTURE; COCULTURE; CYTOLOGY; IMMUNOLOGY; MESENCHYMAL STROMA CELL; METABOLISM; PHYSIOLOGY; YOUNG ADULT;

ADULT; ANTIGENS, CD3; APOPTOSIS; B-LYMPHOCYTES; BONE MARROW CELLS; CARRIER PROTEINS; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; EXTRACELLULAR VESICLES; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERLEUKIN-10; MALE; MESENCHYMAL STROMAL CELLS; RECOMBINANT PROTEINS; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 84949749008     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.3727/096368915X687543     Document Type: Article

References (58)

1. Aggarwal, S.; Pittenger, M. F. Human mesenchymal stemcells modulate allogeneic immune cell responses. Blood 105:1815–1822; 2005
2. Al-Nedawi, K.; Meehan, B.; Kerbel, R. S.; Allison, A.C.; Rak, J. Endothelial expression of autocrine VEGF upon theuptake of tumor-derived microvesicles containing oncogenicEGFR. Proc. Natl. Acad. Sci. USA 106:3794–3799; 2009
3. Al-Nedawi, K.; Meehan, B.; Micallef, J.; Lhotak, V.; May, L.; Guha, A.; Rak, J. Intercellular transfer of the oncogenic receptorEGFRvIII by microvesicles derived from tumour cells.Nat. Cell Biol. 10:619–624; 2008
4. Baraut, J.; Grigore, E. I.; Jean-Louis, F.; Khelifa, S. H.; Durand, C.; Verrecchia, F.; Farge, D.; Michel, L. Peripheralblood regulatory T cells in patients with diffuse systemicsclerosis (SSc) before and after autologous hematopoieticSCT: A pilot study. Bone Marrow Transplant 49:349–354;2014
5. Benvenuto, F.; Ferrari, S.; Gerdoni, E.; Gualandi, F.; Frassoni, F.; Pistoia, V.; Mancardi, G.; Uccelli, A. Humanmesenchymal stem cells promote survival of T cells in aquiescent state. Stem Cells 25:1753–1760; 2007
6. Beyth, S.; Borovsky, Z.; Mevorach, D.; Liebergall, M.; Gazit, Z.; Aslan, H.; Galun, E.; Rachmilewitz, J. Human mesenchymalstem cells alter antigen-presenting cell maturationand induce T-cell unresponsiveness. Blood 105:2214–2219;2005
7. Biancone, L.; Bruno, S.; Deregibus, M. C.; Tetta, C.; Camussi, G. Therapeutic potential of mesenchymal stem cell-derivedmicrovesicles. Nephrol. Dial. Transplant.27:3037–3042; 2012
8. Blois, S. M.; Ilarregui, J. M.; Tometten, M.; Garcia, M.; Orsal, A. S.; Cordo-Russo, R.; Toscano, M. A.; Bianco, G.A.; Kobelt, P.; Handjiski, B.; Tirado, I.; Markert, U. R.; Klapp, B. F.; Poirier, F.; Szekeres-Bartho, J.; Rabinovich, G. A.; Arck, P. C. A pivotal role for galectin-1 in fetomaternaltolerance. Nat. Med. 13:1450–1457; 2007
9. Budoni, M.; Fierabracci, A.; Luciano, R.; Petrini, S.; DiCiommo, V.; Muraca, M. The immunosuppressive effect ofmesenchymal stromal cells on B lymphocytes is mediatedby membrane vesicles. Cell Transplant. 22:369–379; 2013
10. Chamberlain, G.; Fox, J.; Ashton, B.; Middleton, J. Concisereview: Mesenchymal stem cells: Their phenotype, differentiationcapacity, immunological features, and potentialfor homing. Stem Cells 25:2739–2749; 2007
11. Chang, C. J.; Yen, M. L.; Chen, Y. C.; Chien, C. C.; Huang, H. I.; Bai, C. H.; Yen, B. L. Placenta-derived multipotentcells exhibit immunosuppressive properties that areenhanced in the presence of interferon-gamma. Stem Cells 24:2466–2477; 2006
12. Chen, C.; Skog, J.; Hsu, C. H.; Lessard, R. T.; Balaj, L.; Wurdinger, T.; Carter, B. S.; Breakefield, X. O.; Toner, M.; Irimia, D. Microfluidic isolation and transcriptome analysisof serum microvesicles. Lab. Chip 10:505–511; 2010
13. Chen, W.; Jin, W.; Hardegen, N.; Lei, K. J.; Li, L.; Marinos, N.; McGrady, G.; Wahl, S. M. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory Tcells by TGF-beta induction of transcription factor Foxp3.J. Exp. Med. 198:1875–1886; 2003
14. Cocucci, E.; Racchetti, G.; Meldolesi, J. Shedding microvesicles:Artefacts no more. Trends Cell Biol. 19:43–51; 2009
15. Comoli, P.; Ginevri, F.; Maccario, R.; Avanzini, M. A.; Marconi, M.; Groff, A.; Cometa, A.; Cioni, M.; Porretti, L.; Barberi, W.; Frassoni, F.; Locatelli, F. Human mesenchymalstem cells inhibit antibody production induced in vitro byallostimulation. Nephrol. Dial. Transplant. 23:1196–1202;2008
16. Corcione, A.; Benvenuto, F.; Ferretti, E.; Giunti, D.; Cappiello, V.; Cazzanti, F.; Risso, M.; Gualandi, F.; Mancardi, G. L.; Pistoia, V.; Uccelli, A. Human mesenchymal stem cells modulateB-cell functions. Blood 107:367–372; 2006
17. Cuerquis, J.; Romieu-Mourez, R.; Francois, M.; Routy, J. P.; Young, Y. K.; Zhao, J.; Eliopoulos, N. Human mesenchymalstromal cells transiently increase cytokine productionby activated T cells before suppressing T-cell proliferation:Effect of interferon-gamma and tumor necrosis factor-alphastimulation. Cytotherapy 16:191–202; 2014
18. Di Nicola, M.; Carlo-Stella, C.; Magni, M.; Milanesi, M.; Longoni, P. D.; Matteucci, P.; Grisanti, S.; Gianni, A.M. Human bone marrow stromal cells suppress T-lymphocyteproliferation induced by cellular or nonspecific mitogenicstimuli. Blood 99:3838–3843; 2002
19. Doorn, J.; Moll, G.; Le Blanc, K.; van Blitterswijk, C.; deBoer, J. Therapeutic applications of mesenchymal stromalcells: Paracrine effects and potential improvements. TissueEng. Part B Rev. 18:101–115; 2012
20. Eastaff-Leung, N.; Mabarrack, N.; Barbour, A.; Cummins, A.; Barry, S. Foxp3+ regulatory T cells, Th17 effector cells, andcytokine environment in inflammatory bowel disease. J. Clin.Immunol.30:80–89; 2010
21. Fantini, M. C.; Becker, C.; Monteleone, G.; Pallone, F.; Galle, P. R.; Neurath, M. F. Cutting edge: TGF-betainduces a regulatory phenotype in CD4+CD25- T cellsthrough Foxp3 induction and down-regulation of Smad7. J.Immunol.172:5149–5153; 2004
22. Fierabracci, A.; Del Fattore, A.; Luciano, R.; Muraca, M.; Teti, A.; Muraca, M. Recent Advances in mesenchymalstem cell immunomodulation: The role of microvesicles Cell Transplant. 24(2):133–149; 2015
23. Francisco, L. M.; Salinas, V. H.; Brown, K. E.; Vanguri, V. K.; Freeman, G. J.; Kuchroo, V. K.; Sharpe, A. H. PD-L1 regulatesthe development, maintenance, and function of inducedregulatory T cells. J. Exp. Med. 206:3015–3029; 2009
24. Freeman, G. J.; Long, A. J.; Iwai, Y.; Bourque, K.; Chernova, T.; Nishimura, H.; Fitz, L. J.; Malenkovich, N.; Okazaki, T.; Byrne, M. C.; Horton, H. F.; Fouser, L.; Carter, L.; Ling, V.; Bowman, M. R.; Carreno, B. M.; Collins, M.; Wood, C. R.; Honjo, T. Engagement of the PD-1 immunoinhibitoryreceptor by a novel B7 family member leadsto negative regulation of lymphocyte activation. J. Exp.Med. 192:1027–1034; 2000
25. Garin, M. I.; Chu, C. C.; Golshayan, D.; Cernuda-Morollon, E.; Wait, R.; Lechler, R. I. Galectin-1: A key effector ofregulation mediated by CD4+CD25+ T cells. Blood109:2058–2065; 2007
26. Glennie, S.; Soeiro, I.; Dyson, P. J.; Lam, E. W. F.; Dazzi, F. Bone marrow mesenchymal stem cells induce division arrestanergy of activated T cells. Blood 105:2821–2827; 2005
27. Guleria, I.; Khosroshahi, A.; Ansari, M. J.; Habicht, A.; Azuma, M.; Yagita, H.; Noelle, R. J.; Coyle, A.; Mellor, A. L.; Khoury, S. J.; Sayegh, M. H. A critical role forthe programmed death ligand 1 in fetomaternal tolerance.J. Exp. Med. 202:231–237; 2005
28. Highfill, S. L.; Kelly, R. M.; O’Shaughnessy, M. J.; Zhou, Q.; Xia, L.; Panoskaltsis-Mortari, A.; Taylor, P. A.; Tolar, J.; Blazar, B.R. Multipotent adult progenitor cells can suppressgraft-versus-host disease via prostaglandin E2 synthesisand only if localized to sites of allopriming. Blood 114:693–701; 2009
29. Islam, M. N.; Das, S. R.; Emin, M. T.; Wei, M.; Sun, L.; Westphalen, K.; Rowlands, D. J.; Quadri, S. K.; Bhattacharya, S.; Bhattacharya, J. Mitochondrial transfer from bone-marrowderivedstromal cells to pulmonary alveoli protects againstacute lung injury. Nat. Med. 18:759–765; 2012
30. Kadri, T.; Lataillade, J. J.; Doucet, C.; Marie, A.; Ernou, I.; Bourin, P.; Joubert-Caron, R.; Caron, M.; Lutomski, D. Proteomic study of Galectin-1 expression in human mesenchymalstem cells. Stem Cells Dev. 14:204–212; 2005
31. Katsuda, T.; Kosaka, N.; Takeshita, F.; Ochiya, T. The therapeuticpotential of mesenchymal stem cell-derived extracellularvesicles. Proteomics 13:1637–1653; 2013
32. Keating, A. Mesenchymal stromal cells: New directions. Cell Stem Cell 10:709–716; 2012
33. Kilpinen, L.; Impola, U.; Sankkila, L.; Ritamo, I.; Aatonen, M.; Kilpinen, S.; Tuimala, J.; Valmu, L.; Levijoki, J.; Finckenberg, P.; Siljander, P.; Kankuri, E.; Mervaala, E.; Laitinen, S. Extracellular membrane vesicles from umbilicalcord blood-derived MSC protect against ischemic acutekidney injury, a feature that is lost after inflammatory conditioning . J. Extracell. Vesicles 2; 2013
34. Kordelas, L.; Rebmann, V.; Ludwig, A. K.; Radtke, S.; Ruesing, J.; Doeppner, T. R.; Epple, M.; Horn, P. A.; Beelen, D. W.; Giebel, B. MSC-derived exosomes: A noveltool to treat therapy-refractory graft-versus-host disease. Leukemia 28:970–973; 2014
35. Krampera, M.; Cosmi, L.; Angeli, R.; Pasini, A.; Liotta, F.; Andreini, A.; Santarlasci, V.; Mazzinghi, B.; Pizzolo, G.; Vinante, F.; Romagnani, P.; Maggi, E.; Romagnani, S.; Annunziato, F. Role for interferon-gamma in the immunomodulatoryactivity of human bone marrow mesenchymalstem cells. Stem Cells 24:386–398; 2006
36. Krampera, M.; Glennie, S.; Dyson, J.; Scott, D.; Laylor, R.; Simpson, E.; Dazzi, F. Bone marrow mesenchymal stem cellsinhibit the response of naive and memory antigen-specific Tcells to their cognate peptide. Blood 101:3722–3729; 2003
37. Lamparski, H. G.; Metha-Damani, A.; Yao, J. Y.; Patel, S.; Hsu, D. H.; Ruegg, C.; Le Pecq J. B. Production and characterizationof clinical grade exosomes derived from dendriticcells. J. Immunol. Methods 270:211–226; 2002
38. Li, W.; Ren, G.; Huang, Y.; Su, J.; Han, Y.; Li, J.; Chen, X.; Cao, K.; Chen, Q.; Shou, P.; Zhang, L.; Yuan, Z. R.; Roberts, A. I.; Shi, S.; Le, A. D.; Shi, Y. Mesenchymalstem cells: A double-edged sword in regulating immuneresponses. Cell Death Differ. 19:1505–1513; 2012
39. Mathivanan, S.; Simpson, R. J. ExoCarta: A compendium ofexosomal proteins and RNA. Proteomics 9:4997–5000; 2009
40. Meisel, R.; Zibert, A.; Laryea, M.; Gobel, U.; Daubener, W.; Dilloo, D. Human bone marrow stromal cells inhibit allogeneicT-cell responses by indoleamine 2,3-dioxygenase-mediatedtryptophan degradation. Blood 103:4619–4621; 2004
41. Mokarizadeh, A.; Delirezh, N.; Morshedi, A.; Mosayebi, G.; Farshid, A. A.; Mardani, K. Microvesicles derived frommesenchymal stem cells: Potent organelles for induction oftolerogenic signaling. Immunol. Lett. 147:47–54; 2012
42. Nazarov, C.; Lo Surdo, J.; Bauer, S. R.; Wei, C.H. Assessment of immunosuppressive activity of human mesenchymalstem cells using murine antigen specific CD4 andCD8 T cells in vitro. Stem Cell Res. Ther. 4:128; 2013
43. Pedemonte, E.; Benvenuto, F.; Casazza, S.; Mancardi, G.; Oksenberg, J. R.; Uccelli, A.; Baranzini, S.E. Themolecular signature of therapeutic mesenchymal stem cellsexposes the architecture of the hematopoietic stem cellniche synapse. BMC Genomics 8:65; 2007
44. Pittenger, M. F.; Mackay, A. M.; Beck, S. C.; Jaiswal, R.K.; Douglas, R.; Mosca, J. D.; Moorman, M. A.; Simonetti, D. W.; Craig, S.; Marshak, D.R. Multilineage potential ofadult human mesenchymal stem cells. Science 284:143–147;1999
45. Plumas, J.; Chaperot, L.; Richard, M. J.; Molens, J. P.; Bensa, J. C.; Favrot, M. C. Mesenchymal stem cells induce apoptosisof activated T cells. Leukemia 19:1597–1604; 2005
46. Prevosto C.; Zancolli M.; Canevali P.; Zocchi M.R.; Poggi A. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymalstem cell-lymphocyte interaction. Haematologica 92:881–888;2007
47. Rabinovich, G. A.; Alonso, C. R.; Sotomayor, C. E.; Durand, S.; Bocco, J. L.; Riera, C. M. Molecular mechanisms implicatedin galectin-1-induced apoptosis: Activation of theAP-1 transcription factor and downregulation of Bcl-2. Cell Death Differ.7:747–753; 2000
48. Ren, G.; Chen, X.; Dong, F.; Li, W.; Ren, X.; Zhang, Y.; Shi, Y. Concise review: Mesenchymal stem cells and translationalmedicine: Emerging issues. Stem. Cells Transl.Med. 1:51–58; 2012
49. Ren, G.; Zhang, L.; Zhao, X.; Xu, G.; Zhang, Y.; Roberts, A. I.; Zhao, R. C.; Shi, Y. Mesenchymal stem cell-mediatedimmunosuppression occurs via concerted action of chemokinesand nitric oxide. Cell Stem Cell 2:141–150; 2008
50. Renner, P.; Eggenhofer, E.; Rosenauer, A.; Popp, F. C.; Steinmann, J. F.; Slowik, P.; Geissler, E. K.; Piso, P.; Schlitt, H. J.; Dahlke, M. H. Mesenchymal stem cellsrequire a sufficient, ongoing immune response to exert theirimmunosuppressive function. Transplant.Proc. 41:2607–2611; 2009
51. Roberts, G. S.; Kozak, D.; Anderson, W.; Broom, M. F.; Vogel, R.; Trau, M. Tunable nano/micropores for particledetection and discrimination: Scanning ion occlusion spectroscopy . Small 6:2653–2658; 2010
52. Sato, K.; Ozaki, K.; Oh, I.; Meguro, A.; Hatanaka, K.; Nagai, T.; Muroi, K.; Ozawa, K. Nitric oxide plays a criticalrole in suppression of T-cell proliferation by mesenchymalstem cells. Blood 109:228–234; 2007
53. Selmani, Z.; Naji, A.; Zidi, I.; Favier, B.; Gaiffe, E.; Obert, L.; Borg, C.; Saas, P.; Tiberghien, P.; Rouas-Freiss, N.; Carosella, E.D.; Deschaseaux, F. Human leukocyte antigen-G5 secretionby human mesenchymal stem cells is required to suppressT lymphocyte and natural killer function and to induceCD4+CD25highFOXP3+ regulatory T cells. Stem Cells 26:212–222; 2008
54. van der Meel, R.; Krawczyk-Durka, M.; van Solinge, W. W.; Schiffelers, R. M. Toward routine detection of extracellularvesicles in clinical samples. Int. J. Lab. Hematol.36:244–253; 2014
55. Waterman, R. S.; Tomchuck, S. L.; Henkle, S.L.; Betancourt, A.M. A new mesenchymal stem cell (MSC)paradigm: Polarization into a pro-inflammatory MSC1 or anImmunosuppressive MSC2 phenotype. PLoS One 5:e10088;2010
56. Yan, Z.; Zhuansun, Y.; Chen, R.; Li, J.; Ran, P. Immunomodulation of mesenchymal stromal cells on regulatoryT cells and its possible mechanism. Exp. Cell Res.324:65–74; 2014
57. Yi, T.; Song, S. U. Immunomodulatory properties of mesenchymalstem cells and their therapeutic applications. Arch. Pharm. Res. 35:213–221; 2012
58. Zheng, Z. H.; Li, X. Y.; Ding, J.; Jia, J. F.; Zhu, P. Allogeneic mesenchymal stem cell and mesenchymal stemcell-differentiated chondrocyte suppress the responses oftype II collagen-reactive T cells in rheumatoid arthritis. Rheumatology (Oxford) 47:22–30; 2008.